Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. 2007

Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
School of Clinical and Laboratory Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.

Patients receiving warfarin who have unstable control of anticoagulation have a significantly lower intake of dietary vitamin K compared with their stable counterparts. We hypothesized that supplementation with oral vitamin K would improve stability in patients with previously unstable control of anticoagulation. Seventy warfarin-treated patients with unstable anticoagulation control were randomly assigned in a double-blinded fashion to receive a daily amount of 150 mug oral vitamin K or placebo orally for 6 months. Measures of stability of anticoagulation control in the 6-month study period were compared with those in the 6 months immediately prior to it. Vitamin K supplementation resulted in a significantly greater decrease in standard deviation of international normalized ratio (INR) compared with placebo (-0.24 +/- 0.14 vs -0.11 +/- 0.18; P < .001) and a significantly greater increase in percentage time within target INR range (28% +/- 20% vs 15% +/- 20%; P < .01). Anticoagulation control improved in 33 of 35 patients receiving vitamin K supplementation; of these, 19 fulfilled our criteria for having stable control of anticoagulation. However, only 24 of 33 patients receiving placebo demonstrated some degree of improvement, with only 7 patients fulfilling the criteria for having stable control. Concomitant supplementation of vitamin K, perhaps through reducing the relative day-to-day variability in dietary vitamin K intake, can significantly improve anticoagulation control in patients with unexplained instability of response to warfarin.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D004355 Drug Stability The chemical and physical integrity of a pharmaceutical product. Drug Shelf Life,Drugs Shelf Lives,Shelf Life, Drugs,Drug Stabilities,Drugs Shelf Life,Drugs Shelf Live,Life, Drugs Shelf,Shelf Life, Drug,Shelf Live, Drugs,Shelf Lives, Drugs
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D014812 Vitamin K A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Related Publications

Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
April 2008, The Journal of family practice,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
April 2011, Haematologica,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
May 2014, The Cochrane database of systematic reviews,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
February 2004, British journal of haematology,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
November 2015, Heart (British Cardiac Society),
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
July 1980, The New England journal of medicine,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
April 2012, Therapeutic drug monitoring,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
July 2000, Thrombosis and haemostasis,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
February 2000, Thrombosis and haemostasis,
Elizabeth Sconce, and Peter Avery, and Hilary Wynne, and Farhad Kamali
October 2021, The Annals of pharmacotherapy,
Copied contents to your clipboard!